Form 4: Jaguar Health Director Receives Equity Awards

Jaguar Health, Inc. director James J. Bochnowski was granted restricted stock units and stock options on December 11, 2025, aligning his interests with shareholders.

Summary

• James J. Bochnowski, a Director of Jaguar Health, Inc. (JAGX), acquired 6,363 shares of Common Stock in the form of Restricted Stock Units (RSUs) and 6,363 Stock Options.
• The RSUs were granted at a price of $0 and represent a contingent right to receive one share of voting common stock per unit.
• The Stock Options have an exercise price of $1.44 per share and were granted at a price of $0.
• Both the RSU and option grants were approved by the issuer's board of directors on December 11, 2025, under the company's 2014 Stock Incentive Plan.
• The RSUs are scheduled to vest on December 11, 2026.
• The Stock Options will vest ratably on a monthly basis over 12 months from the grant date (December 11, 2025), provided the reporting person continues to serve on the board.
• Following these transactions, Mr. Bochnowski beneficially owns 6,415 shares of Common Stock and 6,363 Stock Options.
• The filing also notes two previous reverse stock splits: a 60-for-1 split on May 23, 2024, and a 25-for-1 split on March 24, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a standard compensation event for a director, which is generally viewed as a neutral to slightly positive development as it aligns the director's interests with shareholders. There are no immediate negative implications, but also no significant positive catalysts.

Positives

• The grant of equity awards to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The awards were granted under an existing 2014 Stock Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

The director's equity awards are subject to future vesting conditions. The 6,363 restricted stock units will vest on December 11, 2026, and the 6,363 stock options will vest ratably over 12 months from December 11, 2025, contingent on continued board service.

Industry Context

This Form 4 filing details routine insider compensation, which is a standard practice across industries to incentivize and retain key personnel. It does not provide broader industry trends but reflects a common mechanism for aligning director interests with company performance.

Corporate Governance

Related Party Transactions

• The equity grants to James J. Bochnowski, a director, constitute a related party transaction as part of his compensation for board service.

Stakeholder Impact

• Shareholders: The equity grants aim to align the director's financial interests with shareholder value creation, potentially leading to more focused decision-making for long-term growth.
• Employees: While not directly impacting employees, such compensation practices can set precedents for broader incentive programs within the company.

Next Steps

• The 6,363 Restricted Stock Units are scheduled to vest on December 11, 2026.
• The 6,363 Stock Options will vest monthly over 12 months from December 11, 2025, subject to the director's continued service.

Key Dates

Keywords

Jaguar Health, JAGX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance